Charlie. you, Thank
our For the for is environment or in have challenge, year prepared lived one through. one challenging great we excelled remarkable the commenting we NeoGenomics resilience take will We'll character XXXX. reflect this by quarter and in then financial questions today's share morning's briefly I'll plan. call, have review pride conclude four XXXX team and no perhaps detailed announcement the XXXX times about thinking of review the in responded of our I'll full-year anticipated succession that our And Kathryn In have and answers. on a about a some could other CEO results. highlights. dynamic more market on obviously year, time provide how When for. for McKenzie current then opportunities of and was in I'll exciting operational and tested. any NeoGenomics most us
quality labs, Our deserve test. They them. work on effort performing up people their dedication laser kept physicians employees want cancer America high call to great work NeoGenomics for showed delivered on and across them. world for around appreciation clearly among a we our recognizing for despite results going NeoGenomics around the patients are start our by saving that lives. passed and team who specimens to and They in and the I this focus the was to all their patients our process and essential continue is serve. There
their oncologist this in were Yet grew fully a by our for patients confident the throughout reluctant of volume to growth in are and that participate year. clinical X% pandemic was in tests volume year-over-year remained labs high rates to pandemic. growth or revenue of to ready see processing total oncology tests, the Many our accelerate business. to good While most affected capable or higher of trials of a of we challenge, great subsides. return core of in even be There's our reason year as the unable
Our incidence business correlation core of we the the rates second year. a in of times recovered volume And nicely COVID-XX direct at lower saw test higher of levels cases. half between
that strong relatively growth under addition, January, measures. in In areas restrictive less were in we achieved geographic
While like the California and were where place. we saw areas in negative in growth Northeast more restrictions
for nationwide increased quickly unfolds. volume of open. volume entire of more more oncology of all Demand and our we're disruptions that in The the year generated revenue South confidence fourth in XX% grew regions we levels giving XXXX and division alone higher of XXXX. Southeast, Florida the XX% this vaccinations Central month may services rates us incidence will lower growth quarter And country to is return allow the and January core our despite as and it to Pharma during did Midwest, in achieve rates the division Informatics combined future hopeful Our XXXX in than strong. is for growth us products when
Interestingly, to these areas service five and just were size next minimal ago. and years fastest Our growth generation of sequencing, product Pharma in continued be Services offerings Informatics.
nearly remained maintaining in books XXXX, XXXX Even year, million the with revenue. we profitable accounted drivers these finished volume year $XX the NeoGenomics entire disruptive full growth for adjusted a infrastructure EBITDA. for of a of cost core and on close and one-third we three As despite
significant Jolla, a trying in Oncology Inivata California acquired have even oncology in over of growth Human Longevity modified We minority and are and made most marketplace. competitive with the La We results. both We're investments or developed the these in proud organic assets launched financial position of made in We of we and strengthened XX our partnership inorganic. proud tests. equally times, that established internally in investment these strategic
members do to a help We to the laboratory endured, see worked hard we all continue America as in continued our through scores. our company build importantly, PCR XXX,XXX performed the COVID-XX to in our and our quickly value success. tests part of and demonstration facility battle company employees our perhaps precious resources most customer we support team times pandemic. culture We culture we for organization. We also invest starts and difficult Carlsbad value reallocated And to and have to positioning survey a satisfaction with know the that a our our that in over
at to for even increase net future Our organic promoter This bodes and critical scores pandemic reached high continue division score XXXX during the time our in an XX. well all growth. net promoter
now final a was The for good increased a quarter of quarter to XX% revenue million. Let's to NeoGenomics. turn $XXX fourth quarter. our XXXX record one attention Fourth the year-over-year
was nearly Importantly, in fourth core oncology our year-over-year quarter XX%. business growth
that pandemic divisions. first quarter recall the saw was growth time three may testing, the for due You year-over-year entirely revenue COVID-XX almost since all PCR fourth to with core our the Quarter began, growth down. In actually in oncology we core of three
oncology Division record. year-over-year Clinical growth driven Services four sequencing grew on Our Quarter to generation up highest volume by X% in quarter of core the XX% next revenue Pharma revenue was XX%.
currently XX% capacity. believe lessened oncology Quarter in a as and area We revenue. X% proliferation now Our in in increased significantly quickly PCR the an that and capacity nearly test as on as the in a testing role this testing reducing year-over-year. paying rapid demand increased of of core exists quarter, core PCR overflow laboratory. over sequential lieu excess revenue growing is declined off of XX% clinical COVID-XX represents are basis our sizable PCR tests services COVID In four, country, testing our this fourth segment investments for volumes
generation other we FISH continued in sequencing testing with next grew While to testing. growth drive particular services nicely, modalities strength in
strong our continues to most the acquire unable While sales new growing volume in customers, supplier challenge members the it's volatility to affect for field. as was be frankly, good a our volumes ability a And to time we and variety disruptions. turnaround to see levels team us, test service experienced actively of remain again, pandemic maintaining as
extremely share. And a customer quarter in that we our reflects increase our strong. remained clinical retention However, slight market volume fourth growth rates believe
Informatics record new contracts. segment revenue and quarter Services in million which includes signed the backlog Pharma Our of bookings fourth had with $XX over ending
diagnostic XX% an which benefit includes our lab companion over exome a next our including China grow. ago. whole oncology diagnostics at we partner to from and Our with place million; sequencing continues companion Services, now year We continue to backlog our in In now increasing new in PPD and of $XXX pharma. projects in positioning investments Pharma our than expertise stands of generation active sequencing XX alliance signed domain as contracts one from bio global global increase our have greater footprint, portfolio to and
our continues I’ll mix. the our results. fuel business Officer Pharma worldwide bio it Quarter financial the to to Informatics been larger of well-positioned as has demand. and discuss details list overall including growing The four rate McKenzie, Financial become it is turn in share and call Chief of revenue some products Our is Kathryn corporate pharma over our other to stronger growth of for is to the of ever increasingly industry than a services now
